Diabetes in treatment with antipsychotic drugs: who is at risk]
Deuschle, M.
MMW Fortschritte der Medizin 147(51-52): 34
2005
ISSN/ISBN: 1438-3276 PMID: 16402705 Document Number: 590364
Document emailed within 1 workday
Related Documents
Wieneke, A.; Bechdolf, A.; Schultze-Lutter, F. 2000: Early intervention in increased risk for schizophrenic illnesses. Multimodal psychotherapy--antipsychotic drugs only in treatment failure MMW Fortschritte der Medizin 142(10): 30-32Firestone, A. 2005: Weight gain and diabetes with "second-generation" antipsychotic drugs Medical Journal of Australia 182(12): 652-653
Baker, R.A.; Pikalov, A.; Tran, Q-Van.; Kremenets, T.; Arani, R.B.; Doraiswamy, P.Murali. 2009: Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis Psychopharmacology Bulletin 42(1): 11-31
Bourin, M. 2006: Pharmacology of antipsychotic drugs L'Encephale 32 Pt 2: S8-S9
Raskind, M.A.; Risse, S.C. 1986: Antipsychotic drugs and the elderly Journal of Clinical Psychiatry 47 Suppl: 17-22
Vieta, E. 2004: Antipsychotic drugs and pregnancy Medicina clinica 123(13): 517-8; author reply 518
Vanden Bussche, G.; Gelders, Y.G.; Heylen, S.L. 1990: Development of new antipsychotic drugs Acta Psiquiatrica y Psicologica de America Latina 36(1-2): 13-25
Wengert, J.W.; Ahmed, I. 1979: Antipsychotic drugs: problems and guidelines Nebraska Medical Journal 64(5): 139-140
Dumortier, G.; Cabaret, W.; Stamatiadis, L.; Saba, G.; Benadhira, R.; Rocamora, J.-F.; Aubriot-Delmas, B.; Glikman, J.; Januel, D. 2002: Hepatic tolerance of atypical antipsychotic drugs L'Encephale 28(6 Part 1): 542-551
Rimón, R.; Leinonen, E. 2002: Should the second generation antipsychotic agents be used as drugs of choice? Duodecim; Laaketieteellinen Aikakauskirja 118(6): 585-590
Lee, B.S. 1986: Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs Journal of Clinical Psychiatry 47(11): 571
Hashimoto, K.; Iyo, M. 2002: Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs Nihon Shinkei Seishin Yakurigaku Zasshi 22(1): 3-13
Tokunaga, H.; Kudo, K.; Imamura, T.; Jitsufuchi, N.; Ohtsuka, Y.; Ikeda, N. 1997: Plasma concentrations of antipsychotic drugs in psychiatric inpatients Nihon Hoigaku Zasshi 51(6): 417-422
Baptista, T. 2002: Mechanisms of weight gain induced by antipsychotic drugs Journal of Clinical Psychiatry 63(3): 245-246
Laux, G. 2003: Pharmaco-economic aspects of antidepressants and antipsychotic drugs Psychiatrische Praxis 30(Suppl 2): S90-S93
Cavanaugh, J.J.; Finlayson, R.E. 1984: Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs Journal of Clinical Psychiatry 45(8): 356-357
Gaebel, W. 1997: Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs International Clinical Psychopharmacology 12(Suppl): S37-S42
Weiden, P.; Aquila, R.; Standard, J. 1996: Atypical antipsychotic drugs and long-term outcome in schizophrenia Journal of Clinical Psychiatry 57(Suppl): 53-60
Lambert, M.; Naber, D.; Perro, C.; Moritz, S.; Krausz, M. 1999: Success of new treatments for schizophrenics, as shown by the example of modern antipsychotic drugs Psychiatrische Praxis 26(Suppl 1): S30-S35
Fomin, V.V. 2012: Fixed dose combinations of antihypertensive drugs and management of risk of development nephropathy in type 2 diabetes mellitus Kardiologiia 52(10): 81-85